John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors.

Alopecia is an autoimmune disorder that causes non-scarring hair loss on the scalp and body that is experienced by almost 2% ...

Hair loss remains a critical issue with only a marginal rate of success. A team of researchers from Australia, Singapore, and ...

Ascentage Pharma Group International’s AAPG share price has dipped by 6.94%, which has investors questioning if this is right ...

A new research paper titled "Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the modulation of MYC mRNA via its interaction with BCL-2/Bax ...